Abstract: The present disclosure encompasses methods for generating cells or tissue from existing cells with one or more mutated variants of Yap. In specific embodiments, the disclosure regards treatment of existing cardiomyocytes with one or more mutated variants of Yap that causes them to divide and generate new cardiomyocytes. In specific cases, the mutated variant of Yap has serine-to-alanine substitutions at 1, 2, 3, 4, 5, 6, or more serines of Yap.

Abstract: An example process includes: receiving a natural language input having a start time and including first and second portions respectively received from the start time to a first time and from the start time to a second time after the first time; determining an end time of the natural language input; executing, at least partially between the first time and the end time, a first task flow based on the first portion, including: obtaining a first executable object representing a first candidate action; executing, at least partially between the second time and the end time, a second task flow based on the second portion, including: obtaining a second executable object representing a second candidate action; in response to determining the end time, selecting a candidate action from a plurality of candidate actions each represented by a respective executable object; and executing the respective executable object representing the selected candidate action.

Abstract: Embodiments of the disclosure include methods and compositions for the renewal of cardiomyocytes by targeting the Hippo pathway. In particular embodiments, an individual with a need for cardiomyocyte renewal is provided an effective amount of a shRNA molecule that targets the Sav1 gene. Particular shRNA sequences are disclosed.

Abstract: Embodiments of the disclosure include methods and compositions related to treating or reducing the severity or delaying the onset of one or more cardiac conditions in a mammal. In particular embodiments, the compositions concern Park2 and its use for a cardiac medical condition. In specific cases, effective amounts of Park2 polynucleotide(s) and/or Park2 polypeptide(s) are provided to an individual in need thereof, including for heart failure, for example. The administration may be locally to the heart, for example.

Abstract: The present disclosure encompasses methods for generating cells or tissue from existing cells with one or more mutated variants of Yap. In specific embodiments, the disclosure regards treatment of existing cardiomyocytes with one or more mutated variants of Yap that causes them to divide and generate new cardiomyocytes. In specific cases, the mutated variant of Yap has serine-to-alanine substitutions at 1, 2, 3, 4, 5, 6, or more serines of Yap.

Abstract: Embodiments of the disclosure include methods and compositions for the renewal of cardiomyocytes by targeting the Hippo pathway. In particular embodiments, an individual with a need for cardiomyocyte renewal is provided an effective amount of a shRNA molecule that targets the Sav1 gene. Particular shRNA sequences are disclosed.

Abstract: The present disclosure encompasses methods for generating cells or tissue from existing cells with one or more mutated variants of Yap. In specific embodiments, the disclosure regards treatment of existing cardiomyocytes with one or more mutated variants of Yap that causes them to divide and generate new cardiomyocytes. In specific cases, the mutated variant of Yap has serine-to-alanine substitutions at 1, 2, 3, 4, 5, 6, or more serines of Yap.

Abstract: Embodiments of the disclosure include methods and compositions for the renewal of cardiomyocytes by targeting the Hippo pathway. In particular embodiments, an individual with a need for cardiomyocyte renewal is provided an effective amount of a shRNA molecule that targets the Sav1 gene. Particular shRNA sequences are disclosed.

Abstract: An example process includes: receiving a natural language input having a start time and including first and second portions respectively received from the start time to a first time and from the start time to a second time after the first time; determining an end time of the natural language input; executing, at least partially between the first time and the end time, a first task flow based on the first portion, including: obtaining a first executable object representing a first candidate action; executing, at least partially between the second time and the end time, a second task flow based on the second portion, including: obtaining a second executable object representing a second candidate action; in response to determining the end time, selecting a candidate action from a plurality of candidate actions each represented by a respective executable object; and executing the respective executable object representing the selected candidate action.

Abstract: Embodiments of the disclosure include methods and compositions related to the proliferation of cardiomyocytes. In particular embodiments, the proliferation of cardiomyocytes is facilitated upon exposure of the cardiomyocytes to agents that affect the sequestering of Yap by dystrophin glycoprotein complex, such agents including those that inhibit DAG1, Yap, or the interaction thereof.

Abstract: Embodiments of the disclosure include methods and compositions for the renewal of cardiomyocytes by targeting the Hippo pathway. In particular embodiments, an individual with a need for cardiomyocyte renewal is provided an effective amount of a shRNA molecule that targets the Sav1 gene. Particular shRNA sequences are disclosed.

Abstract: A system for executing a plurality of transactions comprises a first processor and a memory. The first processor is configured to execute a first transaction comprising: providing a plurality of indications to make a plurality of first changes to a plurality of first records of a database; and committing the first transaction by updating the status of the first transaction in a transaction table while not providing an indication to update the status of the first records from pending. The memory is coupled to the first processor and configured to store the transaction table.

Abstract: Embodiments of the disclosure include methods and compositions related to treating or reducing the severity or delaying the onset of one or more cardiac conditions in a mammal In particular embodiments, the compositions concern Park2 and its use for a cardiac medical condition. In specific cases, effective amounts of Park2 polynucleotide(s) and/or Park2 polypeptide(s) are provided to an individual in need thereof, including for heart failure, for example. The administration may be locally to the heart, for example.

Abstract: A system for analysis and transaction processing includes an interface and a processor. The interface is configured to receive a task. The processor is configured to determine a processing estimate associated with the task by determining required resources for a set of possible processing solutions to perform the task and to determine a task engine based at least in part on the processing estimate. The task engine comprises an analysis engine or a transaction engine. The analysis engine or the transaction engine is used to process the task. The processor is further to provide the task to the task engine.

Abstract: The present disclosure encompasses methods for generating cells or tissue from existing cells with one or more mutated variants of Yap. In specific embodiments, the disclosure regards treatment of existing cardiomyocytes with one or more mutated variants of Yap that causes them to divide and generate new cardiomyocytes. In specific cases, the mutated variant of Yap has serine-to-alanine substitutions at 1, 2, 3, 4, 5, 6, or more serines of Yap.

Abstract: Embodiments of the disclosure include methods and compositions for the renewal of cardiomyocytes by targeting the Hippo pathway. In particular embodiments, an individual with a need for cardiomyocyte renewal is provided an effective amount of a shRNA molecule that targets the Sav1 gene. Particular shRNA sequences are disclosed.

Abstract: A system for analysis and transaction processing includes an interface and a processor. The interface is configured to receive a task. The processor is configured to determine a processing estimate associated with the task by determining required resources for a set of possible processing solutions to perform the task and to determine a task engine based at least in part on the processing estimate. The task engine comprises an analysis engine or a transaction engine. The analysis engine or the transaction engine is used to process the task. The processor is further to provide the task to the task engine.

Abstract: Embodiments of the disclosure include methods and compositions for the renewal of cardiomyocytes by targeting the Hippo pathway. In particular embodiments, an individual with a need for cardiomyocyte renewal is provided an effective amount of a shRNA molecule that targets the Sav1 gene. Particular shRNA sequences are disclosed.

Abstract: A system for executing a plurality of transactions comprises a first processor and a memory. The first processor is configured to execute a first transaction comprising: providing a plurality of indications to make a plurality of first changes to a plurality of first records of a database; and committing the first transaction by updating the status of the first transaction in a transaction table while not providing an indication to update the status of the first records from pending. The memory is coupled to the first processor and configured to store the transaction table.

Abstract: Embodiments of the disclosure include methods and compositions for the renewal of cardiomyocytes by targeting the Hippo pathway. In particular embodiments, an individual with a need for cardiomyocyte renewal is provided an effective amount of a shRNA molecule that targets the Sav1 gene. Particular shRNA sequences are disclosed.